prikaz prve stranice dokumenta Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma
  Preuzmi
PDF 7.45 MB
Znanstveni rad - Izvorni znanstveni rad
Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma
Biomedicines, 10 (2021), 1; 89. https://doi.org/10.3390/biomedicines10010089
Kralj, Tamara; Kokot, Antonio; Zlatar, Mirna; Masnec, Sanja; Kasnik Kovac, Katarina; Milković Periša, Marija; Batelja Vuletić, Lovorka; Giljanović, Ana; Štrbe, Sanja; Sikirić, Sunčana; Balog, Slaven; Sontacchi, Bojan; Sontacchi, Dijana; Buljan, Matko; Lovrić, Eva; Boban Blagaić, Alenka; Škrtić, Anita; Seiwerth, Sven; Sikirić, Predrag Više autora...

Citiranost: ,
Scopus (20)
Citirajte ovaj rad

Kralj, T., Kokot, A., Zlatar, M., Masnec, S., Kasnik Kovac, K., Milković Periša, M. ... Sikirić, P. (2021). Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma. Biomedicines, 10. (1). doi: 10.3390/biomedicines10010089

Kralj, Tamara, et al. "Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma." Biomedicines, vol. 10, br. 1, 2021. https://doi.org/10.3390/biomedicines10010089

Kralj, Tamara, Antonio Kokot, Mirna Zlatar, Sanja Masnec, Katarina Kasnik Kovac, Marija Milković Periša, Lovorka Batelja Vuletić, et al. "Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma." Biomedicines 10, br. 1 (2021). https://doi.org/10.3390/biomedicines10010089

Kralj, T., et al. (2021) 'Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma', Biomedicines, 10(1). doi: 10.3390/biomedicines10010089

Kralj T, Kokot A, Zlatar M, Masnec S, Kasnik Kovac K, Milković Periša M, i sur.. Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma. Biomedicines [Internet]. 31.12.2021. [pristupljeno 04.04.2025.];10(1). doi: 10.3390/biomedicines10010089

T. Kralj, et al., "Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma", Biomedicines, vol. 10, br. 1, Prosinac 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:200123. [Citirano: 04.04.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:200123
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma
AutorTamara Kralj
AutorAntonio Kokot
AutorMirna Zlatar
AutorSanja Masnec
AutorKatarina Kasnik Kovac
AutorMarija Milković Periša
AutorLovorka Batelja Vuletić
AutorAna Giljanović
AutorSanja Štrbe
MBZ: 319335
AutorSunčana Sikirić
AutorSlaven Balog
AutorBojan Sontacchi
AutorDijana Sontacchi
AutorMatko Buljan
AutorEva Lovrić
AutorAlenka Boban Blagaić
AutorAnita Škrtić
AutorSven Seiwerth
AutorPredrag Sikirić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA TEMELJNU I KLINIČKU FARMAKOLOGIJU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PATOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Farmakologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patologija
Sažetak (engleski)
Cauterization of three episcleral veins (open-angle glaucoma model) induces venous congestion and increases intraocular pressure in rats. If not upgraded, one episcleral vein is regularly unable to acquire and take over the whole function, and glaucoma-like features persist. Recently, the rapid upgrading of the collateral pathways by a stable gastric pentadecapeptide BPC 157 has cured many severe syndromes induced by permanent occlusion of major vessels, veins and/or arteries, peripherally and... Više centrally. In a six-week study, medication was given prophylactically (immediately before glaucoma surgery, i.e., three episcleral veins cauterization) or as curative treatment (starting at 24 h after glaucoma surgery). The daily regimen of BPC 157 (0.4 µg/eye, 0.4 ng/eye; 10 µg/kg, 10 ng/kg) was administered locally as drops in each eye, intraperitoneally (last application at 24 h before sacrifice) or per-orally in drinking water (0.16 µg/mL, 0.16 ng/mL, 12 mL/rat until the sacrifice, first application being intragastric). Consequently, all BPC 157 regimens immediately normalized intraocular pressure. BPC 157-treated rats exhibited normal pupil diameter, microscopically well-preserved ganglion cells and optic nerve presentation, normal fundus presentation, normal retinal and choroidal blood vessel presentation and normal optic nerve presentation. As leading symptoms, increased intraocular pressure and mydriasis, as well as degeneration of retinal ganglion cells, optic nerve head excavation and reduction in optic nerve thickness, generalized severe irregularity of retinal vessels, faint presentation of choroidal vessels and severe optic nerve disc atrophy were all counteracted. In conclusion, we claim that the reversal of the episcleral veins cauterization glaucoma appeared as a consequence of the BPC 157 therapy of the vessel occlusion-induced perilous syndrome. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBiomedicines
Brojčani podacivol. 10, br. 1, 89
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines10010089
URN:NBNurn:nbn:hr:105:200123
Datum objave publikacije2021-12-31
URL dokumentahttps://www.mdpi.com/2227-9059/10/1/89
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-07-01 06:54:30
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.